Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based Innovus Pharmaceuticals has introduced its over the counter (OTC) benzocaine-based topical premature ejaculation treatment EjectDelay in the US.
Subscribe to our email newsletter
EjectDelay is an US Food and Drug Administration (FDA) and Health Canada compliant proprietary topical treatment containing the drug benzocaine and indicated for delay of premature ejaculation.
According to the company, the drug typically works within minutes of application to the glans of the penis.
In clinical trials, the application of benzocaine has been demonstrated to delay premature ejaculation by several minutes.
The company said that the product is available online through its website and the product’s specific website (www.ejectdelay.com).
Currently, the company is working with its US co-promotion partner for EjectDelay, Consortia Health, to place this product into urologists’ offices throughout the US.
The product will also be available in the future through Consortia Health’s website, it is available in two sizes in the US as a 2 ounce tube with a retail price of $19.99 and as a 5mL single use packet with a retail price of $2.99.
The EjectDelay product license has been approved in Canada and the company intends to launch the product in the Canadian market in 2014.